LOGIN  |  REGISTER
Cue Biopharma

Information on the total number of voting rights and shares

December 29, 2022 | Last Trade: US$5.71 0.37 -6.09

Mont-Saint-Guibert (Belgium), December 29, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new warrants.

  •  Share capital: EUR 4,440,069.16 
  •  Total number of securities carrying voting rights: 25,846,279 (all ordinary shares) 
  •  Total number of voting rights (= denominator): 25,846,279 (all relating to ordinary shares)  
  •  Number of rights to subscribe to securities carrying voting rights not yet issued: 
    •  55 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 27,500 securities carrying voting rights (all ordinary shares); 
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
    •  450,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 460,500 securities carrying voting rights (all ordinary shares); and
    •  1,350,750 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,350,750 securities carrying voting rights (all ordinary shares); and
    •  700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).  

For further information, please contact:

Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 917 749 1494

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page